FENNEC PHARMACEUTICALS INC. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 58/100
What the filing says
Fennec Pharmaceuticals reported Q2 2026 net product sales of $17.1 million (vs. $9.7 million in Q2 2025, +78% YoY), driven by PEDMARK commercial expansion and new AYA patient accounts. Non-GAAP adjusted EBITDA turned positive at $2.8 million (vs. -$1.2 million loss in Q2 2025). Cash position strengthened to $41.2 million as of June 30, 2026 (vs. $40.1 million on March 31, 2026). Net income was $1.97 million in Q2 2026 vs. loss of $3.15 million in Q2 2025. Selling and marketing expenses increased 123% to $10.7 million to support commercial expansion.
Why this rating
Strong revenue growth (78% YoY) and EBITDA inflection are material for $106M company, showing operational traction. However, still early-stage commercialization with modest absolute scale; lacks transformational M&A, regulatory win, or going-concern event.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.